Skip to main content
TipRanks
Go Ultimate75% OFF

Johnson Chemical Pharmaceutical Works Co., Ltd. (4747) AI Stock Analysis

TW:4747

Johnson Chemical Pharmaceutical Works Co., Ltd.

(TPEx:4747)

Select Model
Rating:51Neutral
Price Target:TWD 21.50â–²(49.83% Upside)
Action:initiatedcoverage
Date:11/10/26

The overall score is constrained by significant operational headwinds. The most impactful factor is the poor cash flow generation, with free cash flow nearly evaporating despite a revenue surge, signaling low earnings quality. This is compounded by bearish technicals, with the stock in a clear downtrend below all major moving averages. A strong, low-debt balance sheet and a reasonable valuation provide some defense, but do not fully offset the deteriorating fundamentals and weak market momentum.

Positive Factors
Strong Revenue GrowthRevenue accelerated 47.8% in 2025 after modest 2024 growth, showing stronger sales momentum. If sustained, this expansion can improve operating scale, support investment in pharmaceutical products, and reinforce the company’s position in specialty and generic markets.
Negative Factors
Sharp Free Cash Flow DeclineFree cash flow fell about 78% to roughly 7.7M in 2025, while covering only about 11% of net income versus 76–79% in 2023–2024. Weak conversion makes reported earnings less dependable for funding investment and shareholder returns over coming quarters.

Johnson Chemical Pharmaceutical Works Co., Ltd. (4747) vs. SPDR S&P 500 ETF (SPY)

-60%-50%-40%-30%-20%-10%0%10%20%TW:4747-53.62%SPY+13.89%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 1.32B
Dividend Yield
3.66%
Average Volume (3M)
235.37K
Price to Earnings (P/E)
-23.4
Beta (1Y)
0.19
Revenue Growth
4.56%
EPS Growth
-172.55%
Country
TW
Employees
188
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Johnson Chemical Pharmaceutical Works Co., Ltd. Business Overview & Revenue Model

Company Description

Johnson Chemical Pharmaceutical Works Co., Ltd., established in 1959 and headquartered in New Taipei City, Taiwan, is a Taiwanese company that engages in the manufacturing, importing, and distribution of pharmaceutical raw materials, active ingredien...

Johnson Chemical Pharmaceutical Works Co., Ltd. Financial Statement Overview

Summary

Financial performance is mixed. The balance sheet is strong with low leverage (D/E 0.15), but this is offset by declining margins, a weak cash conversion ratio (0.19), and a severe 78% drop in free cash flow to just 7.7M, indicating poor earnings quality.

Income Statement

55Neutral

Balance Sheet

72Positive

Cash Flow

35Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue577.93M569.77M611.41M606.71M494.67M411.49M
Gross Profit227.10M228.35M247.97M244.63M204.38M171.92M
EBITDA80.63M93.67M133.19M126.59M101.74M78.30M
Net Income89.38M53.51M84.12M79.70M64.85M49.10M
Balance Sheet
Total Assets2.56B2.09B1.97B1.99B1.04B1.03B
Cash, Cash Equivalents and Short-Term Investments261.73M1.15B1.07B1.09B168.47M202.23M
Total Debt645.00M260.95M150.22M160.83M60.00M80.00M
Total Liabilities820.26M384.37M261.36M320.99M167.56M178.91M
Stockholders Equity1.74B1.71B1.70B1.67B871.66M848.24M
Cash Flow
Free Cash Flow-40.87M7.66M49.68M103.83M29.98M15.06M
Operating Cash Flow24.29M71.71M62.88M136.95M89.69M52.35M
Investing Cash Flow-1.30B-153.76M-12.96M-33.28M-59.92M-38.15M
Financing Cash Flow444.87M61.53M-67.47M815.47M-63.53M-107.64M

Johnson Chemical Pharmaceutical Works Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TW:4747 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TW:8279TW:827969NeutralTWD 2.19B10.63―6.21%-3.92%-29.93%
TW:4148TW:414860NeutralTWD 1.98B10.66―3.40%21.39%54.64%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TW:4747TW:474751NeutralTWD 1.44B-23.41―3.66%4.56%-172.55%
TW:4108TW:410847NeutralTWD 2.07B-47.97――1.10%54.83%

* General Sector Average

Performance Comparison

-40%-20%0%20%TW:4747TW:4108TW:4148TW:6659TW:7888TW:8279Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:4747 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:4747Johnson Chemical Pharmaceutical Works Co., Ltd.14.35-16.88-54.05%
TW:4108Phytohealth Corporation10.30-4.00-27.97%
TW:4148All Cosmos Bio-Tech Holding Corp.29.40-11.51-28.13%
TW:6659Timing Pharmaceutical Co. Ltd.19.35-20.61-51.57%
TW:7888Libo Pharma Corp.24.30-20.85-46.18%
TW:8279Syngen Biotech Co., Ltd.80.50-42.66-34.64%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026